Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

Summary

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of nebulized Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who have respiratory distress.

Timeline

Start

2020-10-28

Primary completion

2021-06-15

Completion

2021-06-15

Outcome

Met primary endpoint

paper The study met its primary endpoint with no AMP5A treatment-related adverse events (AEs) PMID 34775578 ↗

Publications

• Roshon M, Lemos-Filho L, Cherevka H, Goldberg L, Salottolo K, Bar-Or D. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection. Infect Dis Ther. 2022 Feb;11(1):595-605. doi: 10.1007/s40121-021-00562-z. Epub 2021 Nov 14.

Drugs

Indications